Health-Related Quality of Life, Treatment Satisfaction After Ibrutinib Treament for Chronic Lymphocytic Leukemia
The investigators sought to describe HRQOL and treatment satisfaction of ibrutinib-treated patients with CLL in the real-world setting.
Home
Dose-Adjusted EPOCH for B-Cell Lymphomas May Be Safe, Cost Effective in the Outpatient Setting
Researchers found that dose-adjusted (DA-) etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) for B-cell lymphomas can be administered safely in the outpatient setting and that outpatient administration was associated with significant savings relative to inpatient administration. Wenhui Li, PharmD, of the H. Lee Moffitt Cancer Center in Tampa, Florida, and colleagues published their findings in…
Burden of Childhood Cancer Can Be Diminished
Comprehensive scale-up of interventions could avert 6.2 million deaths in children with cancer.
Newly Developed Rapid Point of Care Assay for Acute Promyelocytic Leukemia Diagnosis
Given the difficulty in definitevely diagnosing acute promyelocytic leukemia, researchers sought to develop a rapid point of care diagnostic assay.
Luspatercept Improves Transfusion Burden in Patients with Transfusion-Dependent Beta-Thalassemia
When compared with placebo, luspatercept increased the percentage of patients with transfusion-dependent beta-thalassemia who had a reduction in transfusion burden.
Persistent Leukocytosis as a Marker for Disease Progression in Polycythemia Vera
Although most notably associated with erythrocytosis, hematologic manifestations of polycythemia vera may also include leukocytosis and thrombocytosis.
Polypharmacy Ups Postchemo Hospitalization Risk in Seniors
Findings seen in older patients with prostate, breast, and lung cancers.
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.
FDA Grants First Approval of Convalescent Plasma Therapy in COVID-19 Patient
Houston Methodist first to receive eIND approval for convalescent plasma in individual patient.
Methylation Analysis of cfDNA IDs >50 Cancer Types
Sensitivity increased with increasing stage from 39 percent in stage I to 92 percent in stage IV.
Want to read more?
Please login or register first to view this content.
Next post in General Hematology
